EMOttawa Blog
  • Ottawa Handbook of Emergency Medicine
  • EMOttawa Podcast
  • Point-of-Care Echo
  • Grand Round Summaries
  • Journal Club
  • Commentary
  • Ultrasound
  • Infographics
  • Canadian TIA Score
  • EDI
  • Prehospital and Transport Medicine
  • Ottawa Acute Care Resources
  • About Us
Select Page
Buprenorphine: A guide for ED providers

Buprenorphine: A guide for ED providers

by Max Zworth, Rebecca Seliga | Mar 9, 2023 | Addictions, Critical Care, Featured, Grand Round Summaries, Resuscitation, Toxicology

The opioid epidemic is not new to ED providers, but many will be shocked to learn about the true extent of the harm caused by opioids in Canada.  In the first half of 2022, there were 3556 recorded deaths due to opioid toxicity in Canada. This amounts to 19 deaths...

Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial

by EMOttawa | Jun 19, 2017 | Journal Club, landmark

Journal Club Summary Methodology Score: 4/5 Usefulness Score: 4.5/5 D’Onofrio G, et al JAMA. 2015 Apr 28;313(16):1636-44. Full Article This single, urban center RCT including 329 patients showed that buprenorphine initiated in the ED was more likely to increase...

Sublingual buprenorphine in acute pain management: a double-blind randomized clinical trial

by emottawa | Jul 3, 2012 | Journal Club

Journal Club Summary Methodology: 3.5/5     Usefulness: 2/5 Jalili M, Fathi M, Moradi-Lakeh M, Zehtabchi S. Ann Emerg Med. 2012 Apr;59(4):276-80. PubMed Link   This double blind, double dummy RCT compared sublingual Buprenorphine (0.4 mg) to IV Morphine (5 mg) for...
  • Facebook
  • Twitter
  • Instagram
  • YouTube

Mission Statement

World-Class Emergency Medicine: To provide outstanding compassionate emergency care through practice-changing research and innovative medical education. For more about our department, visit us at EMOttawa.

Categories

Free Open Access Medical Education content by EMOttawa is under a Creative Commons Attribution-NonCommercial ShareAlike 4.0 International License.